Cargando…

Circulating fatty acid synthase: an exploratory biomarker to predict efficacy of the dual HER1/HER2 tyrosine kinase inhibitor lapatinib

Detalles Bibliográficos
Autores principales:	Oliveras-Ferraros, Cristina, Cufí, Sílvia, Sauri-Nadal, Tamara, Barco, Sonia Del, Martin-Castillo, Begoña, Vazquez-Martin, Alejandro, Menendez, Javier A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2011
Materias:	Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3109561/ https://www.ncbi.nlm.nih.gov/pubmed/21349137 http://dx.doi.org/10.1186/bcr2799

Ejemplares similares

Autophagy-related gene 12 (ATG12) is a novel determinant of primary resistance to HER2-targeted therapies: Utility of transcriptome analysis of the autophagy interactome to guide breast cancer treatment
por: Cufí, Sílvia, et al.
Publicado: (2012)

The anti-malarial chloroquine overcomes Primary resistance and restores sensitivity to Trastuzumab in HER2-positive breast cancer
por: Cufí, Sílvia, et al.
Publicado: (2013)

Metformin-induced preferential killing of breast cancer initiating CD44(+)CD24(−/low) cells is sufficient to overcome primary resistance to trastuzumab in HER2+ human breast cancer xenografts
por: Cufí, Sílvia, et al.
Publicado: (2012)

Autophagy Facilitates the Development of Breast Cancer Resistance to the Anti-HER2 Monoclonal Antibody Trastuzumab
por: Vazquez-Martin, Alejandro, et al.
Publicado: (2009)

Metformin: Multi-faceted protection against cancer
por: Del Barco, Sonia, et al.
Publicado: (2011)

Lapatinib, a Dual EGFR and HER2 Tyrosine Kinase Inhibitor, Downregulates Thymidylate Synthase by Inhibiting the Nuclear Translocation of EGFR and HER2
por: Kim, Hwang-Phill, et al.
Publicado: (2009)

Metformin and the ATM DNA damage response (DDR): Accelerating the onset of stress-induced senescence to boost protection against cancer
por: Menendez, Javier A., et al.
Publicado: (2011)

Metformin limits the tumourigenicity of iPS cells without affecting their pluripotency
por: Vazquez-Martin, Alejandro, et al.
Publicado: (2012)

Gerosuppressant Metformin: less is more
por: Menendez, Javier A., et al.
Publicado: (2011)

A novel inhibitor of fatty acid synthase shows activity against HER2+ breast cancer xenografts and is active in anti-HER2 drug-resistant cell lines
por: Puig, Teresa, et al.
Publicado: (2011)

Mitochondrial fusion by pharmacological manipulation impedes somatic cell reprogramming to pluripotency: New insight into the role of mitophagy in cell stemness
por: Vazquez-Martin, Alejandro, et al.
Publicado: (2012)

tabAnti-HER2 (erbB-2) oncogene effects of phenolic compounds directly isolated from commercial Extra-Virgin Olive Oil (EVOO)
por: Menendez, Javier A, et al.
Publicado: (2008)

Metabolomic fingerprint reveals that metformin impairs one-carbon metabolism in a manner similar to the antifolate class of chemotherapy drugs
por: Corominas-Faja, Bruna, et al.
Publicado: (2012)

Cross-suppression of EGFR ligands amphiregulin and epiregulin and de-repression of FGFR3 signalling contribute to cetuximab resistance in wild-type KRAS tumour cells
por: Oliveras-Ferraros, C, et al.
Publicado: (2012)

Efficacy of Lapatinib in Therapy-Resistant HER2-Positive Circulating Tumor Cells in Metastatic Breast Cancer
por: Agelaki, Sofia, et al.
Publicado: (2015)

Correlation of HER2, p95HER2 and HER3 Expression and Treatment Outcome of Lapatinib plus Capecitabine in her2-Positive Metastatic Breast Cancer
por: Han, Sae-Won, et al.
Publicado: (2012)

Antitumor and antiangiogenic effect of the dual EGFR and HER-2 tyrosine kinase inhibitor lapatinib in a lung cancer model
por: Diaz, Roque, et al.
Publicado: (2010)

Effects of Lapatinib on HER2-Positive and HER2-Negative Canine Mammary Carcinoma Cells Cultured In Vitro
por: Leis-Filho, Antonio Fernando, et al.
Publicado: (2021)

Infection with HIV and HCV enhances the release of fatty acid synthase into circulation: evidence for a novel indicator of viral infection
por: Aragonès, Gerard, et al.
Publicado: (2010)

Lapatinib Plasma and Tumor Concentrations and Effects on HER Receptor Phosphorylation in Tumor
por: Spector, Neil L., et al.
Publicado: (2015)

Structural investigations on mechanism of lapatinib resistance caused by HER-2 mutants
por: Verma, Sharad, et al.
Publicado: (2018)

A randomized phase II study of lapatinib + pazopanib versus lapatinib in patients with HER2+ inflammatory breast cancer
por: Cristofanilli, Massimo, et al.
Publicado: (2012)

Microenvironment rigidity modulates responses to the HER2 receptor tyrosine kinase inhibitor lapatinib via YAP and TAZ transcription factors
por: Lin, Chun-Han, et al.
Publicado: (2015)

Preclinical Characteristics of the Irreversible Pan-HER Kinase Inhibitor Neratinib Compared with Lapatinib: Implications for the Treatment of HER2-Positive and HER2-Mutated Breast Cancer
por: Collins, Denis M., et al.
Publicado: (2019)

Predictive value of quantitative HER2, HER3 and p95HER2 levels in HER2-positive advanced breast cancer patients treated with lapatinib following progression on trastuzumab
por: Duchnowska, Renata, et al.
Publicado: (2017)

Molecular effects of lapatinib in patients with HER2 positive ductal carcinoma in situ
por: Estévez, Laura G, et al.
Publicado: (2014)

Molecular effects of Lapatinib in the treatment of HER2 overexpressing oesophago-gastric adenocarcinoma
por: De Silva, Nadeera, et al.
Publicado: (2015)

Metastatic, Her-2 Amplified Lacrimal Gland Carcinoma with Response to Lapatinib Treatment
por: Dennie, Trevor
Publicado: (2015)

Th1 cytokines sensitize HER-expressing breast cancer cells to lapatinib
por: Showalter, Loral E., et al.
Publicado: (2019)

Combining lapatinib and pertuzumab to overcome lapatinib resistance due to NRG1-mediated signalling in HER2-amplified breast cancer
por: Leung, Wing-yin, et al.
Publicado: (2015)

Different mechanisms for resistance to trastuzumab versus lapatinib in HER2- positive breast cancers -- role of estrogen receptor and HER2 reactivation
por: Wang, Yen-Chao, et al.
Publicado: (2011)

An heregulin-EGFR-HER3 autocrine signaling axis can mediate acquired lapatinib resistance in HER2+ breast cancer models
por: Xia, Wenle, et al.
Publicado: (2013)

Synergistic Activity of the HSP90 Inhibitor Ganetespib With Lapatinib Reverses Acquired Lapatinib Resistance in HER2-Positive Breast Cancer Cells
por: Ye, Min, et al.
Publicado: (2021)

Immunohistochemical prediction of lapatinib efficacy in advanced HER2-positive breast cancer patients
por: Duchnowska, Renata, et al.
Publicado: (2015)

Dual HER2 blockade with lapatinib and trastuzumab in combination with chemotherapy in metastatic gastroesophageal adenocarcinoma
por: Cheong, E. Von, et al.
Publicado: (2021)

Lapatinib dysregulates HER2 signaling and impairs the viability of human uveal melanoma cells
por: Shu, Wenying, et al.
Publicado: (2023)

IGF-1R/epithelial-to-mesenchymal transition (EMT) crosstalk suppresses the erlotinib-sensitizing effect of EGFR exon 19 deletion mutations
por: Vazquez-Martin, Alejandro, et al.
Publicado: (2013)

Dual Fatty Acid Synthase and HER2 Signaling Blockade Shows Marked Antitumor Activity against Breast Cancer Models Resistant to Anti-HER2 Drugs
por: Blancafort, Adriana, et al.
Publicado: (2015)

HER2 therapy. Small molecule HER-2 tyrosine kinase inhibitors
por: Spector, Neil, et al.
Publicado: (2007)

Silibinin suppresses EMT-driven erlotinib resistance by reversing the high miR-21/low miR-200c signature in vivo
por: Cufí, Sílvia, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_cij49905b6gm5picurlrbng174